(Q37524058)

20 August 2017

0 references

CYP2D6 genotype and adjuvant tamoxifen: meta-analysis of heterogeneous study populations (English)

1 reference

20 August 2017

0 references

1 reference

27

D Lambrechts

1 reference

20 August 2017

18

P A Fasching

1 reference

20 August 2017

24

U Hamann

1 reference

20 August 2017

3

H Brauch

1 reference

20 August 2017

34

C A Purdie

1 reference

20 August 2017

15

M W Beckmann

1 reference

20 August 2017

14

C B Ambrosone

1 reference

20 August 2017

37

M Schmidt

1 reference

20 August 2017

47

V C Jordan

1 reference

20 August 2017

7

V J Suman

1 reference

20 August 2017

53

J N Ingle

1 reference

20 August 2017

2

M P Goetz

1 reference

20 August 2017

49

R B Altman

1 reference

20 August 2017

51

R M Weinshilboum

1 reference

20 August 2017

M A Province

1

1 reference

20 August 2017

D A Flockhart

4

1 reference

20 August 2017

J M Hebert

5

1 reference

20 August 2017

R Whaley

6

1 reference

20 August 2017

W Schroth

8

1 reference

20 August 2017

S Winter

9

1 reference

20 August 2017

H Zembutsu

10

1 reference

20 August 2017

T Mushiroda

11

1 reference

20 August 2017

W G Newman

12

1 reference

20 August 2017

M-T M Lee

13

1 reference

20 August 2017

J-Y Choi

16

1 reference

20 August 2017

A-S Dieudonné

17

1 reference

20 August 2017

R Ferraldeschi

19

1 reference

20 August 2017

L Gong

20

1 reference

20 August 2017

E Haschke-Becher

21

1 reference

20 August 2017

A Howell

22

1 reference

20 August 2017

L B Jordan

23

1 reference

20 August 2017

K Kiyotani

25

1 reference

20 August 2017

P Krippl

26

1 reference

20 August 2017

A Latif

28

1 reference

20 August 2017

U Langsenlehner

29

1 reference

20 August 2017

W Lorizio

30

1 reference

20 August 2017

P Neven

31

1 reference

20 August 2017

A T Nguyen

32

1 reference

20 August 2017

B-W Park

33

1 reference

20 August 2017

P Quinlan

35

1 reference

20 August 2017

W Renner

36

1 reference

20 August 2017

M Schwab

38

1 reference

20 August 2017

J-G Shin

39

1 reference

20 August 2017

J C Stingl

40

1 reference

20 August 2017

P Wegman

41

1 reference

20 August 2017

S Wingren

42

1 reference

20 August 2017

A H B Wu

43

1 reference

20 August 2017

E Ziv

44

1 reference

20 August 2017

G Zirpoli

45

1 reference

20 August 2017

A M Thompson

46

1 reference

20 August 2017

Y Nakamura

48

1 reference

20 August 2017

M M Ames

50

1 reference

20 August 2017

M Eichelbaum

52

1 reference

20 August 2017

T E Klein

54

1 reference

20 August 2017

International Tamoxifen Pharmacogenomics Consortium

55

1 reference

20 August 2017

language of work or name

English

0 references

publication date

23 September 2013

1 reference

Clinical Pharmacology & Therapeutics

20 August 2017

1 reference

20 August 2017

95

1 reference

20 August 2017

2

1 reference

20 August 2017

216-227

1 reference

CYP2D6 metabolism and patient outcome in the Austrian Breast and Colorectal Cancer Study Group trial (ABCSG) 8.

20 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3904554

Tamoxifen use in postmenopausal breast cancer: CYP2D6 matters

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3904554

CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3904554

CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3904554

Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3904554

Genotype-guided tamoxifen dosing increases active metabolite exposure in women with reduced CYP2D6 metabolism: a multicenter study

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3904554

Statistical design of personalized medicine interventions: the Clarification of Optimal Anticoagulation through Genetics (COAG) trial

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3904554

CYP2D6 polymorphisms as predictors of outcome in breast cancer patients treated with tamoxifen: expanded polymorphism coverage improves risk stratification

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3904554

Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3904554

Cytochrome P450 2D6 activity predicts discontinuation of tamoxifen therapy in breast cancer patients

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3904554

Differential patterns of allelic loss in estrogen receptor-positive infiltrating lobular and ductal breast cancer

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3904554

Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3904554

Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3904554

Tamoxifen: a most unlikely pioneering medicine

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3904554

Meta-analysis in clinical trials

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3904554

Comprehensive CYP2D6 genotype and adherence affect outcome in breast cancer patients treated with tamoxifen monotherapy

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3904554

Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 trial.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3904554

Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3904554

Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3904554

A region of deletion on chromosome 22q13 is common to human breast and colorectal cancers.

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3904554

Activity Levels of Tamoxifen Metabolites at the Estrogen Receptor and the Impact of Genetic Polymorphisms of Phase I and II Enzymes on Their Concentration Levels in Plasma

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3904554

Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 trial

3 December 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24060820

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Allelic losses of loci at 3p25.1, 8p22, 13q12, 17p13.3, and 22q13 correlate with postoperative recurrence in breast cancer

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24060820

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24060820

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/CLPT.2013.186

1 reference

20 August 2017

1 reference

20 August 2017

PubMed publication ID

24060820

1 reference